知临集团 APM 深 沪
等待开盘 05-16 09:30:00 美东时间
0.8234
-0.023
-2.67%
华盛通- 最 高0.9098
- 今 开0.83
- 成交量 8992股
- 最 低 0.8137
- 昨 收 0.846
- 总市值 670.56万
- 52周最高 4.47
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.65
- 委 比 -37.50%
- 总股本 814.38万
- 历史最高 332.80
- 量 比 0.42
- 振 幅 11.36%
- 历史最低 0.46
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多知临集团2025年第四季度财报发布日期待定
经济观察网 纳斯达克上市公司知临集团尚未公布2025年第四季度财报的具体发布日期，投资者需关注后续业绩公告。 以上内容基于公开资料整理，不构成投资建议。
04-15 04:38
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group Limited received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share. The company has been granted a 180-day grace period until September 1, 2026, to regain compliance. Aptorum intends to evaluate all options, including a reverse stock split, to restore compliance and maintain its Nasdaq listing.
03-06 21:30
Aptorum Group, DiamiR Biosciences, Instant NanoBiosensors Collaborate To Validate Instant's Automated APOE Testing Platform
Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative
02-02 21:06
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
DiamiR Biosciences and Instant NanoBiosensors (INB) have partnered to validate INB’s automated APOE testing platform for clinical use in DiamiR’s certified laboratory. The APOE gene, particularly the ε4 allele, is a key genetic risk factor for Alzheimer’s disease. This collaboration aims to enhance testing capabilities and explore broader applications. DiamiR, set to become a subsidiary of Aptorum Group, and INB envision this partnership as a fou...
02-02 13:00
Aptorum Group Issues Amended SEC Filing on DiamiR Merger
Aptorum Group Ltd. has issued an amendment to its previous report, clarifying details related to its Agreement and Plan of Merger with DiamiR Biosciences Corp. The amendment includes additional inform...
2025-12-06 05:31
DiamiR To Highlight Potential Of Brain-Enriched, Inflammation-Associated microRNAs As Epigenetic Biomarkers Of Neurodegeneration At CTAD Conference
DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage
2025-11-19 21:05
Andean Precious Metals Sees Q3 Production Rise, Optimizes Operations for Year-End
Andean Precious Metals ( ($TSE:APM) ) just unveiled an announcement. Andean Pre...
2025-10-16 06:40
Aptorum Group Announces Merger with DiamiR Biosciences
The latest announcement is out from Aptorum Group ( ($APM) ). Aptorum Group Lim...
2025-10-16 05:29
Aptorum Group Announces $2M Registered Direct Offering Of 1M Shares At $2 Each, Plus $4M Upside From 2M Unregistered Warrants In Concurrent Private Placement
$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrantsNEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum
2025-10-10 21:56
Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update
Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and custo...
2025-10-09 20:55
